###begin article-title 0
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Activation of P2X7-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 162 164 162 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 295 297 295 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 426 428 426 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
The study tested the hypothesis that apoptosis can prevent and control growth of neoplastic cells. Previous studies in-vitro have shown that the pro-apoptotic P2X7 receptor regulates growth of epithelial cells. The specific objective of the present study was to understand to what degree the P2X7 system controls development and growth of skin cancer in vivo, and what cellular and molecular mechanisms are involved in the P2X7 action.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 229 230 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 500 502 500 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
Skin neoplasias in mice (papillomas, followed by squamous spindle-cell carcinomas) were induced by local application of DMBA/TPA. Experiments in-vitro utilized cultured epidermal keratinocytes generated from wild-type or from P2X7-null mice. Assays involved protein immunostaining and Western blots; mRNA real-time qPCR; and apoptosis (evaluated in situ by TUNEL and quantified in cultured keratinocytes as solubilized DNA or by ELISA). Changes in cytosolic calcium or in ethidium bromide influx (P2X7 pore formation) were determined by confocal laser microscopy.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 41 43 41 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 345 346 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 596 598 596 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 1049 1051 1049 1051 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 678 683 <span type="species:ncbi:10090">mouse</span>
###xml 709 714 <span type="species:ncbi:10090">mouse</span>
(a) Co-application on the skin of the P2X7 specific agonist BzATP inhibited formation of DMBA/TPA-induced skin papillomas and carcinomas. At the completion of study (week 28) the proportion of living animals with cancers in the DMBA/TPA group was 100% compared to 43% in the DMBA/TPA+BzATP group. (b) In the normal skin BzATP affected mainly P2X7-receptor - expressing proliferating keratinocytes, where it augmented apoptosis without evoking inflammatory changes. (c) In BzATP-treated mice the degree of apoptosis was lesser in cancer than in normal or papilloma keratinocytes. (d) Levels of P2X7 receptor, protein and mRNA were 4-5 fold lower in cancer tissues than in normal mouse tissues. (e) In cultured mouse keratinocytes BzATP induced apoptosis, formation of pores in the plasma membrane, and facilitated prolonged calcium influx. (f) The BzATP-induced apoptosis, pore-formation and augmented calcium influx had similar dose-dependence for BzATP. (g) Pore formation and the augmented calcium influx were depended on the expression of the P2X7 receptor, while the BzATP-induced apoptosis depended on calcium influx. (h) The BzATP-induced apoptosis could be blocked by co-treatment with inhibitors of caspase-9 and caspase-3, but not of caspase-8.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 7 8 7 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 208 210 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 399 401 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 432 433 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
###xml 321 326 <span type="species:ncbi:10090">mouse</span>
(a) P2X7-dependent apoptosis is an important mechanism that controls the development and progression of epidermal neoplasia in the mouse. (b) The P2X7-dependent apoptosis is mediated by calcium influx via P2X7 pores, and involves the caspase-9 (mitochondrial) pathway. (c) The diminished pro-apoptotic effect of BzATP in mouse cancer keratinocytes is possibly the result of low expression of the P2X7 receptor. (d) Activation of P2X7-dependent apoptosis, e.g. with BzATP could be a novel chemotherapeutic growth-preventive modality for papillomas and epithelial cancers in vivo.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 473 475 473 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 559 560 559 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
The current theory of growth of epithelial cells predicts regulation by the concerted effects of mitogenic stimuli and apoptosis [1,2]. Apoptosis is a homeostatic process orchestrated by the host's genome of selective cell deletion without stimulating inflammatory response [3-5]. Dysregulation of apoptotic cell-death has been implicated in states of disease and in the neoplastic transformation [6,7]. Among the pro-apoptotic systems that operate in epithelia [8] the P2X7 is an important mechanism because the receptor is expressed by proliferating cells [9], and activation of the receptor induces apoptosis that controls directly growth of the epithelial cells [10].
###end p 11
###begin p 12
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 302 304 302 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 490 491 490 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The P2X7 receptor is a membrane-bound, ligand-operated channel [11-13]. The natural ligand of the receptor is ATP [11,12] which is present in the extracellular fluid of epithelial cells at high nanomolar, low micromolar levels [14-18]. In contrast to other types of ATP receptors, activation of the P2X7 receptor requires relatively high concentrations of the ligand [12]. However, studies in epithelial cells of the female reproductive tract showed a threshold effect and activation of P2X7-mediated apoptosis already by nanomolar concentrations of ATP [8,18], suggesting that ATP levels which are present in the extracellular fluid suffice to activate the receptor.
###end p 12
###begin p 13
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 122 124 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 145 147 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 173 175 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 201 203 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 255 257 244 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 312 314 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 361 363 350 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 450 453 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 460 461 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 525 527 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 528 530 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 531 533 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Binding of the ligand to the P2X7 receptor can activate various cell-specific signaling cascades, including the IL-1beta [19], TNFalpha - TRAIL [20], and the p38, JNK/SAPK [21] and NF-kappaB cascades [22]. However, a unique effect of activation of the P2X7 receptor is formation of pores in the plasma membrane [12]. In uterine epithelial cells formation of P2X7 receptor pores induces apoptosis by a mechanism that involves uncontrolled influx of Ca2+ via P2X7-pores and activation of the mitochondrial - caspase-9 pathway [13,18,23].
###end p 13
###begin p 14
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 173 175 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 397 399 397 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 482 484 482 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 563 565 563 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 756 758 756 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Until recently relatively little was known about the biological role of the P2X7 in vivo, and particularly in the epidermis. Earlier studies suggested involvement of the P2X7 receptor in the inflammatory and immune processes since the receptor is expressed in Langerhans and inflammatory dendritic epidermal cells [24] and in cultured immature dendritic epidermal cells [25]. Overexpression of P2X7 was found in lesional skin of psoriasis and atopic dermatitis, where an intense P2X7 immunoreactivity was confined to the cell membrane of the basal layer [26]. P2X7 may also play a role in chemokine secretion by normal keratinocytes but available data are inconsistent. Inoue et al [27] reported that treatment of cultured normal keratinocytes with the P2X7 specific agonist 2',3'-0-(4-benzoylbenzoyl)-adenosine 5'-triphosphate (BzATP) increased IL-6 release, while Pastore et al [26] described that BzATP down-modulated chemokine secretion.
###end p 14
###begin p 15
###xml 37 39 37 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 239 241 239 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 466 468 466 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 290 295 <span type="species:ncbi:9606">human</span>
###xml 526 531 <span type="species:ncbi:9606">human</span>
Studies also suggested a role for P2X7 in the control of epidermal growth, but most studies were observational. The P2X7 receptor is expressed in normal [28], in precancerous epidermal tissues [29], and in skin cancer cells [26,30,31]. P2X7 receptors were detected already in 8-11 week-old human fetal epidermis; they colocalized with caspase-3 and with periderm cells positive for transferase-mediated dUTP nick-end-labeling (TUNEL) [32]. Co-localization of the P2X7 with apoptosis-related markers was also reported in adult human epidermis [28], and recent studies reported BzATP-induced cell death in normal and cancer keratinocytes, presumably by augmented apoptosis [29,30].
###end p 15
###begin p 16
###xml 57 59 57 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 178 180 178 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 246 248 246 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
Although existing observational data suggest that the P2X7 may regulate growth of epithelial cells, no previous studies investigated experimentally the biological role of the P2X7 receptor in vivo. The present study tested the hypothesis that P2X7 controls epidermal cell growth in vivo by apoptosis.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Experiments in mice in vivo
###end title 18
###begin p 19
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 443 450 <span type="species:ncbi:191423">clipper</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
The experiments were approved by the Case Western Reserve University (CWRU) Institutional Animal Care and Use Committee (IACUC) protocol [2006-0141], and all experiments were done in accordance with CWRU IACUC policy, following nationally and internationally recognized guidelines. Experiments utilized 6-8 weeks old wild-type FVB female mice (Charles River, Wilmington, MA). The animal's dorsal skin (~3 x 5 cm) was shaved using Oster animal clipper (Mountain Home, AR) followed by weekly application of Nair hair remover lotion . Skin neoplasia in the mice were induced by the "Two-Step" method, which involved tumor initiation by local treatment with 7,12-dimethyl-benz(a)anthracene (DMBA), followed by tumor promotion with local treatment of 12-O-tetradecanoylphorbol-13-acetate (TPA) [e.g. [33]].
###end p 19
###begin p 20
###xml 172 173 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 231 232 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 355 356 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 583 584 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 585 587 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Treatments included the application of one or more of the following drugs, directly onto the shaved dorsal skin: DMBA (50 mug/200 mul acetone [950 muM, 190 nmol, 3.3 mug/cm2]); TPA (3 mug/200 mul acetone [20 muM, 4 nmol, 0.2 mug/cm2]); BzATP (14.3 mug/200 mul of 2.3/1 vol/vol solution of propylene-glycol [PG]/ethanol [EtOH] [100 muM, 20 nmol, 1.0 mug/cm2]); or the BzATP vehicle only (200 mul of PG/EtOH). DMBA was applied once, while TPA and BzATP were applied twice a week. The concentration/dose of BzATP and frequency of treatments were chosen based on data in cultured cells [8,23].
###end p 20
###begin p 21
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
The First experiment (Experiment-1) included three groups of animals: Control (no treatment, n = 13); DMBA plus TPA (n = 15); and DMBA/TPA plus BzATP (n = 12). Treatments with BzATP began two weeks prior to the DMBA/TPA treatments. Endpoints were determined at 0-12 (Papilloma Phase) and 14-28 weeks (Cancer Phase) after DMBA. Endpoints were the incidence and prevalence of lesions, as well as the mean lesion size in each living animal. Biopsy of skin papilloma was done in one living animal using mini rotary ElliptiPunch blade (HUOT, Menomonee Falls, WI). Criteria for euthanasia (by cervical dislocation) prior to week 28 were according to Montgomery guidelines [34], including animals with excessive tumor burden, or with ulcerated lesions regardless of size that were bleeding, necrosed, or infected. The experiment was terminated at week 28, when all remaining living animals were euthanized. After death, representative samples were obtained from all skin lesions as follows: From the DMBA/TPA group 4 papillomas and 26 cancer samples; and from the DMBA/TPA-BzATP group 2 papillomas and 12 cancer samples. All animals underwent postmortem exam for the presence of metastases and non-epidermal tumors (none were found).
###end p 21
###begin p 22
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
Lesions developed at 0-12 weeks were defined papillomas based on the actual histological diagnosis in one case, the typical morphological appearance, and the extensive experience gained by others using this model and methodology [33,35]. Lesions developed at 14-28 weeks were defined either as cancers (as diagnosed in each case at the time of death), or as non-cancerous lesions, including existing or involuting papillomas (diagnosed at the time of death) or lesions that disappeared prior to death.
###end p 22
###begin p 23
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Experiments 2 and 3 studied the effects of BzATP in normal mice. Experiment-2 included one group of five animals. The shaved dorsal skin was divided into equal anterior and posterior areas. Each animal was treated with BzATP, applied locally twice a week for 4 weeks on the anterior skin area; vehicle only was applied in parallel twice a week for 4 weeks on the posterior skin area. At the end of the experiment animals were euthanized and strips were obtained from each animal from the anterior and posterior treated dorsal skin areas.
###end p 23
###begin p 24
Experiment-3 included two groups of 5 normal animals, Control (vehicle only) and BzATP. Animals were treated for 16 weeks, and after euthanasia strips were obtained from each animal from the treated dorsal skin areas. In addition, blood samples were obtained from each animal from the retro-bulbar venous complex for plasma alanine aminotransferase (ALT, glutamic pyruvic transaminase [GPT]), and aspartate aminotransferase (AST, glutamic oxalacetic transaminase [GOT]) assays.
###end p 24
###begin p 25
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
Skin tissues from animals of Experiments 1-3 were assayed for histology (H&E), P2X7-receptor immunoreactivity, and in-situ TUNEL.
###end p 25
###begin title 26
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Experiments using cultured mouse keratinocytes
###end title 26
###begin p 27
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 313 314 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 340 345 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 436 437 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 454 455 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
The experiments utilized primary cultures of epidermal keratinocytes generated from 6-8 weeks old wild-type C57Bl mice (Charles River, Wilmington, MA); from P2X7-/-Pfizer mice [36], constructed by deletion of amino acids 506-532 of the C-terminus which is critical for P2X7-mediated apoptosis [12,23]; or from P2X7-/-GSK mice, which have a lacZ gene inserted at the beginning of exon 1, resulting knockout of the receptor, [37]. The P2X7-/-Pfizer and P2X7-/-GSK mice were generated on the C57Bl background.
###end p 27
###begin p 28
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 393 395 392 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 407 409 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 444 446 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
Primary cultures of mouse keratinocytes were generated by the collagenase-EDTA method as described [38], with minor modifications. Ventral superficial skin areas involving the full epidermis and part of the dermis were scraped and the cell suspension was washed by PBS and filtered through a 40-mum cell strainer. Following repeated washes and spinning cells were plated at a density of 1 x 105 cells per cm2 on type-I collagen-coated filters [23] and used for experiments after 24-48 hours.
###end p 28
###begin p 29
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 147 149 147 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 467 469 467 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 535 537 535 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 138 143 <span type="species:ncbi:10090">mouse</span>
P2X7-specific antisense oligonucleotides (ASO) and random control oligonucleotides (RCO) were designed from the published sequence of the mouse P2X7 gene [39] (AJ009823) using a previously described method [40]. The sequences of the 20-mer ASO that would hybridize to the coding region of exon 13 (nt 1467-1486), and the RCO were as follows: ASO - GGC GTA CCG CAG CAA CGT AG; RCO - TAA GTA CTG CAG CTA CGT AC (designed such that no cross-hybridization against the P2X7 gene would occur). To assess the effects of the ASO and RCO on P2X7 mRNA expression, cultured cells were treated for 14 hours with or without 100 muM ASO or RCO.
###end p 29
###begin title 30
Protein and mRNA methods
###end title 30
###begin p 31
###xml 16 18 16 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 214 216 214 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 265 267 265 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 294 296 294 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 485 486 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 925 927 925 927 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
The receptor P2X7 protein in tissues cross sections was detected by immunostaining as described [9,38]. The specificity of staining was previously shown in terms of incubations in the absence or presence of the P2X7 antigen peptide, where co-incubation with the P2X7 antigen peptide blocked P2X7 immunoreactivity [9]. Immunofluorescence was captured in a fluorescence microscope Nikon Eclipse 80i (Nikon, Melville, NY), and image analysis of the immunofluorescence data was described [9,38]. Briefly, fields of interest were captured and saved in Adobe Photoshop. Pictures were scanned using UN-SCAN-IT software (Silk Scientific, Orem, UT) by choosing 5 representative fields for each picture. Fields of interest were chosen in reference to the epithelial component of the tissue, as determined by switching to phase microscopy of the same slide. Light intensity in each field was digitized, and average pixel density for P2X7 per field was determined using the program software.
###end p 31
###begin p 32
###xml 51 53 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Western blotting of cell lysates using the anti-P2X7 antibody, and densitometry of the P2X7-specific 75 KDa band (relative to glyceraldehyde-3-phosphate dehydrogenase, GAPDH) were done as was previously described [23].
###end p 32
###begin p 33
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 181 183 181 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 560 574 548 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
###xml 581 583 561 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 144 149 <span type="species:ncbi:10090">mouse</span>
Total RNA was extracted by RNeasy mini kit (Qiagen, Valencia, CA), and two-step real-time qPCR was carried out as described [23]. The following mouse-specific primers were used: P2X7 receptor, forward 5'-TTC CAG GAA GCA GGA GAG AA-3', reverse 5'-ATA CTT CAA CGT CGG CTT GG-3' (annealing at 58degreesC, 2 min). GAPDH, forward 5'-TGT TGC CAT CAA TGA CCC C-3', reverse 5'-ATG AGT CCT TCC ACG ATA CC-3' (annealing at 61degreesC, 1 min). Relative quantification (RQ) was calculated using Applied Biosystems SDS software (Foster City, CA) based on the equation RQ= 2-DeltaDeltaCt where Ct is the threshold cycle to detect fluorescence.
###end p 33
###begin title 34
Apoptosis assays
###end title 34
###begin p 35
###xml 182 184 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 264 266 255 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
TUNEL assays in tissues cross sections were performed using DeadEndtrade mark Fluorometric TUNEL System (Promega, Madison, WI) according to the manufacturer's protocol. For TUNEL-P2X7 co-staining, tissue cross sections were first assayed for TUNEL, followed by P2X7 immunostaining. The modified combined method resulted in only negligible cross fluorescence interference.
###end p 35
###begin p 36
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
Apoptosis of cultured mouse keratinocytes was quantified in terms of percent solubilized DNA [8], or by using the commercial cell-death detection ELISA kit (Roche Applied Science, Nutley, NJ) [23].
###end p 36
###begin title 37
ALT and AST assays
###end title 37
###begin p 38
ALT and AST assays used Liquid Reagent kits (Pointe Scientific, Canton MI), and were performed according to the supplier instructions.
###end p 38
###begin title 39
###xml 21 23 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
Cytosolic Calcium (Ca2+i) and Ethidium-Bromide assays
###end title 39
###begin p 40
###xml 13 15 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 15 17 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 326 328 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 764 766 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 936 938 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 200 205 <span type="species:ncbi:10090">mouse</span>
###xml 550 555 <span type="species:ncbi:10090">mouse</span>
Changes in Ca2+i in cultured cells were determined in terms of changes in intracellular Fluo-4 fluorescence using dynamic confocal laser scanning microscopy as was previously described [23]. Cultured mouse keratinocytes were loaded with 5 muM Fluo-4/AM, and imaged with a Zeiss LSM 510 inverted real-time confocal microscope [23]. Images were collected at 488 nm/505 nm (exc/emi) at intervals of 10 to 15 seconds after treatment with 100 muM BzATP, added to the perfusate. For ethidium bromide influx experiments, glass-bottomed dishes cultured with mouse keratinocytes were placed in the microscope. Images (collected at 488 nm/505 nm [exc/emi]) were taken before, and at intervals of 30 seconds after adding 5 muM ethidium bromide to the perfusate as described [23]. Average fluorescence intensity was quantified from collated images using MetaVue softeware (Fryer Company Inc., Huntley, IL) by subtracting the basal intensity value [23].
###end p 40
###begin title 41
DNA synthesis assay
###end title 41
###begin p 42
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Changes in DNA synthesis were determined in terms of [3H]thymidine incorporation as described [10]. The radioactivity (dpm/mg Protein, determined by Bio-Rad Protein Assay solution [Hercules, CA]) of triplicated samples was determined by beta scintillation counting (Beckman LS1801 scintillation counter).
###end p 42
###begin title 43
Data Analysis
###end title 43
###begin p 44
###xml 766 768 764 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 782 784 780 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 821 823 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 875 876 871 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 961 963 955 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 978 979 972 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
The proportion of living animals with papillomas or cancerous lesions in Experiment 1 was calculated at each week throughout the study period and compared between groups by chi-square or Fisher's exact test. Time-to-event data were used to assess differences in the formation of cancerous lesions and the Kaplan-Meier method (with log-rank test) was used to compare differences between groups. Mean number of lesions per animal was calculated at each week and compared between groups by independent samples t-test. In addition, repeated-measure ANOVA was used to examine the effect of time and number of lesions between groups. Mean lesion size was compared similarly for weeks 0-12. For weeks 14-28, non-cancerous and cancerous lesions were categorized as </= 10 mm3 versus > 10 mm3 and the proportion of lesions > 10 mm3 in living animals was compared between groups by chi2-square or Fisher's exact test. Cancerous lesions were also categorized as </= 200 mm3 versus > 200 mm3. Cancer development (for weeks 14-28) and Survival rates (for weeks 0-28) were evaluated using the Kaplan-Meier method and compared between groups by log-rank test. For cultured cells data, significance of differences between groups was estimated by t-test, or by one-way or two-way ANOVA with Tukey-Kramer Multiple Comparisons post test analysis.
###end p 44
###begin title 45
Supplies
###end title 45
###begin p 46
###xml 197 199 197 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 265 267 265 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 171 177 <span type="species:ncbi:9986">Rabbit</span>
###xml 332 338 <span type="species:ncbi:9986">rabbit</span>
###xml 441 445 <span type="species:ncbi:9925">goat</span>
###xml 451 457 <span type="species:ncbi:9986">rabbit</span>
All chemicals, unless specified otherwise, were obtained from Sigma Chemical (St. Louis, MO). Primary antibodies for the immunostaining and Western blots were as follows: Rabbit polyclonal anti-P2X7 receptor antibody, which recognizes the functional full length P2X7 receptor [23] was from Alomone Laboratories (Jerusalem, Israel); rabbit anti-GAPDH antibody was from BD Transduction Laboratories (Lexington, KY). The secondary antibody was goat anti-rabbit Alexa Fluro antibody (Invitrogen, ) [23]. Leu-Glu-His-Asp-O-methyl-fluoromethylketone (LEHD-FMK), Ile-Glu-Thr-Asp-O-methyl-fluoromethyketone (IETD-FMK), Benzyloxy-valine-alanine-aspartate-O-methyl-fluoromethylketone (zVAD-FMK), and Asp-Glu-Val-Asp-O-methyl-fluoromethylketone (DEVD-FMK) were from Calbiochem (La Jolla, CA), and were used at a concentration of 50 muM.
###end p 46
###begin title 47
Results
###end title 47
###begin title 48
BzATP modulates DMBA/TPA skin effects (Experiment-1)
###end title 48
###begin p 49
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
Local administration of DMBA/TPA induced formation of skin lesions, papillomas at weeks 5-12, and squamous spindle-cell carcinomas afterwards (Figs. 1, 2). About one thirds of the papillomas involuted after week 14 and the remaining persisted either as non-cancerous papillomas, or have transformed to cancerous lesions (Figs. 1, 2, 3, 4, 5, 6). All cancerous lesions arose from pre-existing papillomas. None of the animals in the control group had developed skin lesions (Fig. 1A).
###end p 49
###begin p 50
###xml 0 118 0 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative pictures of DMBA/TPA &#8211; induced skin lesions in mice in-vivo, and the effects of co-treatment with BzATP</bold>
###xml 130 132 130 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D </bold>
###xml 136 138 136 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E </bold>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Representative pictures of DMBA/TPA - induced skin lesions in mice in-vivo, and the effects of co-treatment with BzATP. Arrows in D and E point to involuting papillomas.
###end p 50
###begin p 51
###xml 0 158 0 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative cross-sections, evaluated histologically by H&amp;E, of DMBA/TPA &#8211; induced skin lesions in mice in-vivo, and the effects of co-treatment with BzATP</bold>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Representative cross-sections, evaluated histologically by H&E, of DMBA/TPA - induced skin lesions in mice in-vivo, and the effects of co-treatment with BzATP.
###end p 51
###begin p 52
###xml 0 172 0 172 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the proportion of living mice with skin lesions (Experiment-1)</bold>
###xml 177 178 177 178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 240 242 240 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 246 247 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 462 464 462 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 468 470 468 470 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the proportion of living mice with skin lesions (Experiment-1). In A, skin lesions at 0-12 weeks of treatment were papillomas. In A and B, skin lesions at 14-28 weeks of treatment were grouped either as cancerous lesions (squamous spindle-cell carcinomas, circles), or as non-cancerous lesions (existing or involuting papillomas, triangles). Values in A and B are means; standard deviation (SD) ranged 3-11%.
###end p 52
###begin p 53
###xml 0 174 0 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the mean number of skin lesions per living animal (Experiment-1)</bold>
###xml 228 232 228 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A-C </bold>
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the mean number of skin lesions per living animal (Experiment-1). Definitions of lesions were as in Fig. 4. Values in A-C are means; SD ranged 5-9%.
###end p 53
###begin p 54
###xml 247 249 247 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 264 266 264 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 0 284 0 284 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the mean lesion size at 0&#8211;12 weeks of treatment (A); and on the proportion of living mice with total lesions volume per animal of &gt; 10 mm<sup>3 </sup>(B) or &gt; 200 mm<sup>3 </sup>(C) (Experiment-1)</bold>
###xml 338 342 338 342 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A-C </bold>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the mean lesion size at 0-12 weeks of treatment (A); and on the proportion of living mice with total lesions volume per animal of > 10 mm3 (B) or > 200 mm3 (C) (Experiment-1). Definitions of lesions were as in Fig. 3. Values in A-C are means; SD ranged 2-18%.
###end p 54
###begin p 55
###xml 0 201 0 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the time-to-event of cancer state (A) and on the animals' survival rates (B) (Experiment-1)</bold>
Summary of the effects of local treatments with DMBA/TPA (black symbols) or DMBA/TPA+BzATP (white symbols) on the time-to-event of cancer state (A) and on the animals' survival rates (B) (Experiment-1). Definitions of lesions were as in Fig. 3.
###end p 55
###begin p 56
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
Co-treatment with BzATP, applied locally on skin areas exposed to DMBA/TPA altered the incidence and pattern of skin lesions (Figs. 1, 2, 3, 4, 5, 6). To evaluate the effects of BzATP, changes in skin lesions in the DMBA/TPA and DMBA/TPA+BzATP groups were compared relative to the length of treatment. Since formation of papillomas and cancerous lesions was time-related, with a marked cut-off at weeks 13-14 (Fig. 3A), data were analyzed separately for weeks 0-12 and 14-28.
###end p 56
###begin title 57
Proportion of animals with lesions
###end title 57
###begin p 58
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 529 531 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 674 676 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 834 836 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1012 1014 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1188 1190 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
At weeks 0-12 the proportion of living animals with papillomas tended to be lower in the DMBA/TPA+BzATP group than in the DMBA/TPA group, and analysis of the proportion having a papilloma separately gave a significant (p < 0.05) difference at week 5 of treatment (Fig. 3A; 48 +/- 12% versus 80 +/- 10%, respectively). The proportion of living animals with any skin lesion at weeks 14-21 was similar in the two groups, being initially influenced by the death of two animals with cancers in the DMBA/TPA group at weeks 13-14 (Fig. 3A, filled circles). However, the proportion of living animals with any skin lesion differed significantly among the groups in weeks 22-28 (Fig. 3A). During that period of time the proportion of living animals with non-cancerous lesions (existing and involuting papillomas) decreased in both groups (Fig. 3B). In contrast, the proportion of living animals with cancerous lesions in the DMBA/TPA group increased steadily while in the DMBA/TPA+BzATP group it decreased over time (Fig. 3B). For example, in week 28 the proportions of living animals with cancerous lesions in the DMBA/TPA and the DMBA/TPA+BzATP groups were 100% and 43 +/- 9%, respectively (Fig. 3B).
###end p 58
###begin title 59
Mean number of lesions
###end title 59
###begin p 60
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 493 495 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 625 627 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 730 732 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 802 804 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
In both groups the mean number of papillomas per living animal increased at weeks 0-12, but the increase in the DMBA/TPA+BzATP group tended to be smaller than in the DMBA/TPA group (Fig. 4A). Independent samples t-test revealed a significant difference at week 10 (2.3 +/- 0.5 and 1.2 +/- 0.4 papillomas per animal [mean +/- SD], respectively, p < 0.04). Also, repeated measures ANOVA yielded a significant time effect (p < 0.01) for the DMBA/TPA and DMBA/TPA+BzATP curves at weeks 0-12 (Fig. 4A). At weeks 14-28 the mean number of total lesions per living animal was not significantly different between the two groups (Fig. 4A). In both groups the mean number of non-cancerous lesions decreased over the 14-28 weeks period (Fig. 4B), while the mean number of cancerous lesions remained the same (Fig. 4C).
###end p 60
###begin title 61
Mean lesion size
###end title 61
###begin p 62
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 276 281 276 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B, C</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 568 570 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 804 806 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
Animals in both groups were compared relative to the total size of lesions (in mm3) per animal. In both groups the mean total papillomas size per living animal increased at weeks 0-12, but the increase in the DMBA/TPA+BzATP group was smaller than in the DMBA/TPA group (Figs. 1B, C, 5A). Independent samples t-test revealed significant differences at all weeks for mean total papillomas size (p < 0.01-0.03, Fig. 5A). For example, in week 12 mean total papillomas size (in mm3) per animal was 5.8 +/- 1.1 versus 3.4 +/- 1.0 (mean +/- SD), respectively (p < 0.01, Fig. 5A). Likewise, repeated measures ANOVA yielded a significant time effect (p < 0.01); a significant group effect (p < 0.02); and a non-significant time*group interaction effect (p > 0.1), for the DMBA/TPA and DMBA/TPA+BzATP curves (Fig. 5A). The latter analysis indicates non-interacting trends for the two curves.
###end p 62
###begin p 63
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D&#8211;I</xref>
###xml 338 340 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 533 535 533 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 698 700 698 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 829 831 829 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 935 937 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
At weeks 14-28 the variability of the lesions sizes among the two groups was large, due to the excessive growth of some lesions unproportionally to others (e.g. Figs. 1D-I). This precluded us from comparing means of lesion size among the two groups. However, since most non-cancerous lesions in both groups tended to be smaller than 10 mm3 and the proportion of animals with non-cancerous lesions of > 10 mm3 was low (< 10%) in both groups (Fig. 5B, triangles), data of the proportion of living animals with cancerous lesions > 10 mm3 were compared among the two groups. Figure 5B shows a significantly smaller proportion of living animals in the DMBA/TPA+BzATP group with cancerous lesions > 10 mm3 after week 23 than in the DMBA/TPA group. For example, in week 28 the proportion of living animals with cancerous lesions > 10 mm3 were 81% +/- 8% compared to 16 +/- 4% in the DMBA/TPA and the DMBA/TPA+BzATP groups, respectively (Fig. 5B).
###end p 63
###begin p 64
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1I</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1H</xref>
###xml 469 471 469 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
Interestingly, five mice in the DMBA/TPA+BzATP group survived despite having developed relatively large cancerous lesions (e.g. Fig. 1I), while maintaining normal weight and exhibiting normal behavior. In contrast, most mice in the DMBA/TPA group with already smaller cancerous lesions (e.g. Fig. 1H) had to be euthanized per protocol due to poor general condition and excessive tumor burden. Analysis of the proportion of living animals with cancerous lesions > 200 mm3 showed a tendency for higher proportion of animals in the DMBA/TPA+BzATP group than in the DMBA/TPA group (Fig. 5C), but the differences did not reach statistical significance.
###end p 64
###begin title 65
Summary of the trends of cancer development and survival rates
###end title 65
###begin p 66
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
Using time-to-event data analysis it was found that development of cancerous lesions was significantly slower and lower in the DMBA/TPA+BzATP group than in the DMBA/TPA group (Fig. 6A).
###end p 66
###begin p 67
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
Survival curves for the DMBA/TPA and DMBA/TPA+BzATP groups were generated based on event (death from cancer) and time-to-event (in weeks) for each group. Log-rank test was used to compare the survival curves based on group. The overall survival rates among the two groups did not differ statistically, although there was a tendency of earlier deaths in the DMBA/TPA group compared to the DMBA/TPA+BzATP group (Fig. 6B).
###end p 67
###begin title 68
Animals' weights
###end title 68
###begin p 69
There were no significant differences in animals' weights among the control or the DMBA/TPA and DMBA/TPA+BzATP treatment groups over the course of 28 weeks (not shown).
###end p 69
###begin title 70
Morphological and histological skin changes
###end title 70
###begin p 71
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A&#8211;I</xref>
###xml 112 117 112 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A, B</xref>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B&#8211;E</xref>
###xml 374 379 374 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C, D</xref>
###xml 482 487 482 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D, E</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2E</xref>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2F&#8211;I</xref>
###xml 717 721 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1F&#8211;I</xref>
There were no significant differences in the morphological (Figs. 1A-I) and histological characteristics (Figs. 2A, B) of the unaffected normal skin in the DMBA/TPA and the DMBA/TPA+BzATP groups. Similarly there were no significant differences in the morphological (Figs. 1B-E) and histological characteristics of papillomas in the DMBA/TPA and DMBA/TPA+BzATP groups (Figs. 2C, D). In both groups after week 14 some papillomas remained intact while other started to involute (Figs. 1D, E, 2E). However, in both groups most papillomas (about two third) underwent cancerous transformation to squamous cell carcinomas with spindle-cell changes (Figs. 2F-I). There were no significant changes in the morphological (Figs. 1F-I) and histological characteristics (not shown) of cancers in the two groups.
###end p 71
###begin title 72
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
P2X7 receptor expression is lower in mouse skin cancer tissues
###end title 72
###begin p 73
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 332 334 332 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 548 553 548 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A, B</xref>
###xml 574 576 574 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 767 772 767 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C, D</xref>
###xml 791 793 791 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 906 911 906 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7E, F</xref>
###xml 942 944 942 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 990 992 990 992 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7G</xref>
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
Cellular effects of BzATP are mediated mainly by the P2X7 receptor [11,12]. The present data showed that mouse normal, papilloma, and cancer skin cells express the P2X7 receptor, but levels of the receptor in cancer tissues were significantly lower than in normal skin or papilloma tissues (Fig. 7). Immunostaining with the anti P2X7 receptor antibody of tissue cross sections containing normal skin revealed intense immunoreactivity that localized predominantly in the epidermis within proliferating keratinocytes and epidermal hair shafts (Figs. 7A, B). In papillomas, P2X7 immunoreactivity was intense (Fig. 7C), similar to normal tissues (Fig. 7A), and it localized predominantly within proliferating keratinocytes at the base of the developing papillomas (Figs. 7C, D). In contrast, P2X7 immunoreactivity in cancer tissues was significantly lesser than in normal epidermal or papilloma tissues (Figs. 7E, F), and data analysis of the P2X7 immunostaining revealed a four fold lesser P2X7 immunoreactivity in cancer than in normal tissues (Fig. 7G).
###end p 73
###begin p 74
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 0 172 0 172 <bold xmlns:xlink="http://www.w3.org/1999/xlink">P2X<sub>7 </sub>immunoreactivity in mouse normal skin (A), papilloma (C), and skin cancer tissues (E) (Experiment-1); B, D, F are parallel cross sections, respectively, stained by H&amp;E</bold>
###xml 174 175 174 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 192 194 192 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 337 338 335 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 343 345 341 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 481 483 479 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 560 562 558 560 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H </bold>
###xml 800 801 796 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 850 851 846 847 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I</bold>
###xml 856 858 852 854 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 989 993 983 987 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G-I </bold>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 363 368 <span type="species:ncbi:10090">mouse</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 844 848 <span type="species:ncbi:10090">mice</span>
P2X7 immunoreactivity in mouse normal skin (A), papilloma (C), and skin cancer tissues (E) (Experiment-1); B, D, F are parallel cross sections, respectively, stained by H&E. G. Analysis of P2X7 immunoreactivity compared among paired histologically normal and cancerous tissues. Bars are means (+/- SD) of levels in tissues of five mice. H. P2X7 protein assays in mouse normal and cancer skin tissues. Lysates fractionated by gel electrophoresis were immunoblotted with the anti P2X7 antibody and membranes were reprobed with the anti GAPDH antibody. Insert in H shows Western immunoblot of lysates of histologically normal and cancerous tissues obtained from the same animal. Similar results were obtained in tissues of two additional mice. Bars show means (+/- SD) of densitometry results of the P2X7-specific 75 KDa bands in tissues of three mice. I. P2X7 mRNA levels (relative to GAPDH mRNA) (means +/- SD) in histologically normal and cancerous tissues obtained from three animals. In G-I data in the normal tissues were normalized in each case to an arbitrary value of 10. * - p < 0.01. AU - arbitrary units.
###end p 74
###begin p 75
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7H</xref>
###xml 235 237 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 302 304 302 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7I</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 429 431 429 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 461 466 <span type="species:ncbi:10090">mouse</span>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
The immunostaining data were confirmed by Western blot experiments. Assays of the P2X7-specific 75 KDa band revealed a five fold lower density in cancer tissues than in normal tissues (Fig. 7H). Further confirmation was obtained by P2X7 mRNA experiments where qPCR assays revealed a five fold lower P2X7 mRNA/GAPDH mRNA levels in normal tissues than in cancer tissues (Fig. 7I). Collectively, the data in Fig. 7 indicate that P2X7 receptor expression levels in mouse skin cancer tissues are four-five fold lower than in mouse normal skin tissues.
###end p 75
###begin title 76
BzATP augments apoptosis in the normal skin (Experiments 2 and 3)
###end title 76
###begin p 77
###xml 198 200 198 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
To better understand the cellular effects of BzATP in vivo, experiments investigated the effects of BzATP in the normal mouse on skin morphology and histology; on the immunoreactivities with the P2X7 antibody; and on apoptosis.
###end p 77
###begin p 78
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 528 533 528 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8B, C</xref>
In animals of Experiment-2, BzATP was applied twice weekly for 4 weeks on the anterior region of the shaved dorsal skin and each animal served as its own control by having vehicle-containing solution applied twice weekly for 4 weeks on the posterior region of the shaved dorsal skin (Fig. 8A). Treatments with BzATP or the vehicle solution had no visible morphological effect on the skin (Fig. 8A), and histological evaluation showed no differences in cross sections obtained from the BzATP-treated or control skin areas (Figs. 8B, C).
###end p 78
###begin p 79
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects in mice in-vivo of local treatment with BzATP on skin apoptosis (Experiment-2)</bold>
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 520 521 520 521 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 545 546 545 546 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 584 588 584 588 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B, C</bold>
###xml 598 601 598 601 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D-G</bold>
###xml 614 618 614 618 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H, I</bold>
###xml 630 633 630 633 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D-G</bold>
###xml 681 685 681 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E, G</bold>
###xml 716 720 716 720 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D, F</bold>
###xml 749 753 749 753 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D, E</bold>
###xml 772 776 772 776 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F, G</bold>
###xml 831 833 831 833 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G </bold>
###xml 982 986 982 986 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H, I</bold>
###xml 1023 1025 1023 1025 <bold xmlns:xlink="http://www.w3.org/1999/xlink">I </bold>
###xml 11 15 <span type="species:ncbi:10090">mice</span>
###xml 91 95 <span type="species:ncbi:10090">Mice</span>
Effects in mice in-vivo of local treatment with BzATP on skin apoptosis (Experiment-2). A. Mice (n = 5) were treated with BzATP, applied locally twice a week for 4 weeks on the shaved anterior skin area, and with the vehicle (Control) applied in parallel on the shaved posterior skin area. The horizontal line shows schematically separation of the anterior and posterior dorsal skin regions. At the end of the experiment animals were euthanized and skin cross sections were generated from each animal from the anterior (B, BzATP) and posterior (C, Control) dorsal skin areas for H&E (B, C), TUNEL (D-G), and DAPI (H, I) staining. D-G: TUNEL staining of BzATP-treated skin tissues (E, G) and of Control skin tissues (D, F), processed in the absence (D, E) or the presence (F, G) of the TUNEL active reagent TdT (Promega). Arrows in G show enhanced TUNEL staining in epidermal cells of the basal/parabasal layers (horizontal arrow) and of epidermal hair shaft cells (vertical arrow). H, I: DAPI (nuclear) staining. Arrows in I point to nuclei of epidermal cells in basal/parabasal regions of the epidermis at advanced stages of condensation, fragmentation and pyknosis. Data in A-I are representative of similar results in five animals.
###end p 79
###begin p 80
###xml 221 226 221 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8D, E</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8F</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8G</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8I</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8H</xref>
###xml 203 208 <span type="species:ncbi:10090">mouse</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
Experiment-2 also studied the effects of local treatment with BzATP on skin apoptosis in vivo by TUNEL staining. The negative control experiment showed minimal auto-fluorescence in cross sections of the mouse skin (Figs. 8D, E). In skin cross sections of non-treated mice, only faint TUNEL staining decorated the epidermis (Fig. 8F). In contrast, in skin cross sections of BzATP-treated mice numerous epidermal basal/parabasal cells and epidermal hair shaft cells stained TUNEL positive (Fig. 8G). Additionally, DAPI stains of cross sections of BzATP-treated skin revealed greater proportion of nuclei at advanced stages of condensation, fragmentation and pyknosis (Fig. 8I) compared to controls (Fig. 8H).
###end p 80
###begin p 81
###xml 277 282 277 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A, C</xref>
###xml 305 310 305 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B, D</xref>
###xml 417 419 417 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 443 448 443 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9E, F</xref>
###xml 573 578 573 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9G, H</xref>
###xml 623 624 623 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 705 707 705 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 731 736 731 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9I, J</xref>
###xml 764 769 764 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3K, L</xref>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
In animals of Experiment-3, BzATP was applied twice weekly for 16 weeks on the entire shaved dorsal skin. The control group included mice that were treated only with the vehicle. Similar to Experiment-2, treatment with BzATP had no significant effect on skin morphology (Figs. 9A, C) and histology (Figs. 9B, D), compared to treatment with the vehicle only. Also, treatment with BzATP had no significant effect on P2X7 immunoreactivity (Figs. 9E, F). However, treatment with BzATP increased the number of TUNEL stained epidermal basal/parabasal and hair shaft cells (Figs. 9G, H), similar to the result in Experiment-2. P2X7-TUNEL co-staining showed that the increased TUNEL staining co-localized with P2X7 immunoreactivity (Figs. 9I, J [low magnification], Figs. 3K, L [higher magnification]).
###end p 81
###begin p 82
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects in mice in-vivo of local treatment with BzATP on skin apoptosis (Experiment-3)</bold>
###xml 205 209 205 209 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A, B</bold>
###xml 248 252 248 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C, D</bold>
###xml 377 381 377 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B, D</bold>
###xml 390 391 390 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 411 414 411 414 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E-L</bold>
###xml 427 429 427 429 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J </bold>
###xml 481 483 481 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 11 15 <span type="species:ncbi:10090">mice</span>
Effects in mice in-vivo of local treatment with BzATP on skin apoptosis (Experiment-3). Animals (n = 5) were treated for 16 weeks either with BzATP, applied locally twice a week on the shaved dorsal skin (A, B) or with the vehicle (Control, n = 5, C, D). At the end of the experiment animals were euthanized and strips were obtained from each animal dorsal skin areas for H&E (B, D) and P2X7/TUNEL co-staining (E-L). Arrows in J show increased TUNEL staining co-localizing with P2X7 immunoreactivity in epidermal cells of the basal/parabasal layers (horizontal arrow) and of epidermal hair shaft cells (vertical arrow). Assays were repeated 3-5 times with similar trends.
###end p 82
###begin p 83
###xml 31 32 31 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
Collectively, the data in Fig. 9 indicate that treatment with BzATP, applied locally twice a week on the shaved dorsal skin of normal mice, up-regulated apoptosis of proliferating epidermal and hair shaft keratinocytes. However, in the normal mouse skin the BzATP treatment and the augmented apoptosis did not affect morphology or histology of the skin.
###end p 83
###begin p 84
###xml 358 363 <span type="species:ncbi:10090">mouse</span>
Treatments with BzATP for 4 weeks (Experiment-2) or for 16 weeks (Experiment-3) had no significant effects on the behavior of the animals, on their feeding habits, or on their body weight (not shown). In addition, in animals of Experiment-3 mean ALT and AST plasma levels were similar among the BzATP and control groups, and were in the normal range for the mouse (not shown).
###end p 84
###begin title 85
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
Effects of BzATP on P2X7 expression and TUNEL in papilloma and cancer tissues
###end title 85
###begin p 86
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 164 170 164 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A, B</xref>
###xml 193 195 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 328 334 328 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A, B</xref>
###xml 411 417 411 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10E, F</xref>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
P2X7 immunoreactivities in cross sections of papillomas did not differ in intensity among specimens obtained from DMBA/TPA- or DMBA/TPA+BzATP - treated mice (Figs. 10A, B). The intensity of P2X7 immunoreactivity in cross sections of skin cancers was significantly weaker than in normal (Fig. 7A) and in papilloma tissues (Figs. 10A, B), but it did not differ among the DMBA/TPA and DMBA/TPA+BzATP groups (Figs. 10E, F).
###end p 86
###begin p 87
###xml 39 41 39 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 0 142 0 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of treatments with BzATP on P2X<sub>7 </sub>expression and apoptosis in DMBA/TPA &#8211; induced skin papillomas (A-D) and cancers (E-H) (Experiment-1)</bold>
###xml 194 205 194 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C, D, G, H </bold>
###xml 236 246 236 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A, B, E, F</bold>
Effects of treatments with BzATP on P2X7 expression and apoptosis in DMBA/TPA - induced skin papillomas (A-D) and cancers (E-H) (Experiment-1). Assays were repeated 4 times with similar trends. C, D, G, H are parallel cross sections to A, B, E, F, respectively.
###end p 87
###begin p 88
###xml 62 65 62 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10C</xref>
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10G</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8F</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9G</xref>
###xml 274 277 274 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10D</xref>
###xml 304 307 304 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10H</xref>
###xml 533 536 533 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10D</xref>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
TUNEL staining was weak in cross sections of papillomas (Fig. 10C) and cancer tissues (Fig. 10G) from the DMBA/TPA group, similar to findings in cross sections of normal skin (Figs. 8F, 9G). In contrast, TUNEL staining was more intense in cross sections of papillomas (Fig. 10D) and cancer tissues (Fig. 10H) from the DMBA/TPA+BzATP group. In papillomas obtained from mice of the DMBA/TPA+BzATP group, enhanced TUNEL staining decorated basal/parabasal layers of keratinocytes outgrowing at the base of the developing papilloma (Fig. 10D).
###end p 88
###begin title 89
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Mechanism of BzATP-augmented apoptosis in mouse keratinocytes
###end title 89
###begin title 90
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
Dependence of BzATP-augmented apoptosis on the expression of the P2X7 receptor
###end title 90
###begin p 91
###xml 186 187 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 212 213 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 226 227 226 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
To better understand the mechanism of BzATP pro-apoptotic skin effects, experiments utilized cultured primary mouse keratinocytes that were obtained from wild-type mice, and from the P2X7-receptor - deficient P2X7-/-Pf and P2X7-/-GSK mice.
###end p 91
###begin p 92
###xml 197 200 196 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 222 225 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11A</xref>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
In wild-type mouse keratinocytes BzATP augmented apoptosis in a dose-related manner; effects began at BzATP levels as low as 50 nM, reaching maximal effect at 100-250 muM with an estimated BzATP EC50 of about 10 muM (Fig. 11A).
###end p 92
###begin p 93
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of BzATP on apoptosis in cultured mouse keratinocytes</bold>
###xml 185 186 185 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 378 379 376 377 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 480 482 477 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 526 528 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 740 742 734 736 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 777 779 771 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 841 842 835 836 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 985 986 979 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1001 1002 995 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1034 1035 1028 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1184 1186 1176 1178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 1190 1192 1182 1184 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 1261 1263 1253 1255 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
###xml 227 232 <span type="species:ncbi:10090">mouse</span>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
###xml 883 888 <span type="species:ncbi:10090">mouse</span>
###xml 1060 1064 <span type="species:ncbi:10090">mice</span>
Effects of BzATP on apoptosis in cultured mouse keratinocytes. In all experiments levels of apoptosis were normalized to an arbitrary value of 2 in control cells. AU - arbitrary units. A. BzATP dose-response effect in cultured mouse normal (wild-type, C57Bl) keratinocytes (means +/- SD, n = 3). Cells were treated with one of the indicated concentrations of BzATP for 8 hours. B. Cultured mouse normal keratinocytes (wild-type, C57Bl) were pre-treated with 100 muM anti-sense P2X7 oligonucleotides (ASO) or random-control P2X7 oligonucleotides (RCO) for 14 hours followed by 8 hours treatment with 100 muM BzATP. Control - cells treated with the vehicle of the ASO. Values are means (+/- SD) of 3 experiments for each condition. Insert in B is Western immunoblot with anti-P2X7 antibody of lysates of cells treated with ASO or RCO (n = 2). C. BzATP time-response effect in cultured mouse normal keratinocytes (wild-type, C57Bl; filled triangles), or in keratinocytes obtained from P2X7-deficient (P2X7-/-Pfizer [empty circles] or P2X7-/-GSK [filled circles]) mice (both in the C57Bl background). Values are means (+/- SD) of 3 experiments for each condition. Changes in apoptosis in A and B were determined in terms of solubilized DNA; changes in apoptosis in C were determined using cell-death detection ELISA.
###end p 93
###begin p 94
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 108 111 108 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11B</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 295 298 295 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11B</xref>
###xml 372 373 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 400 403 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11B</xref>
###xml 480 483 480 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11B</xref>
Pre-treatment with P2X7-receptor anti-sense oligonucleotide decreased expression of the P2X7-receptor (Fig. 11B, insert); it also inhibited baseline apoptosis (which most likely is induced paracrinologically by ATP secreted by the cells [8]), and blocked the pro-apoptotic effect of BzATP (Fig. 11B). Pre-treatment with random-control oligonucleotides had no effect on P2X7-receptor expression (Fig. 11B, insert), or on baseline apoptosis and the apoptosis induced by BzATP (Fig. 11B).
###end p 94
###begin p 95
###xml 80 82 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 168 169 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 255 256 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 353 356 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11C</xref>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
The dependence of the pro-apoptotic effect of BzATP on the expression of the P2X7 receptor was further demonstrated in experiments using keratinocytes obtained from P2X7-receptor - deficient mice. Compared to wild-type mouse keratinocytes, in both the P2X7-/-Pf and P2X7-/-GSK keratinocytes treatment with 100 muM BzATP failed to induce apoptosis (Fig. 11C).
###end p 95
###begin title 96
###xml 16 18 16 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
Formation of P2X7 pores
###end title 96
###begin p 97
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 270 272 270 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 330 332 330 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 429 431 429 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 225 230 <span type="species:ncbi:10090">mouse</span>
In uterine epithelial cells [23], as well as in other types of cells [11-13], P2X7-receptor - dependent apoptosis involves agonist-induced acute calcium influx via P2X7 pores. To understand whether BzATP-induced apoptosis in mouse keratinocytes involves formation of P2X7 pores, experiments compared activation by BzATP of the P2X7 receptor (in terms of BzATP-induced increase in cytosolic calcium [23]), and the formation of P2X7 pores (in terms of BzATP-induced increase in the influx of ethidium bromide [23]).
###end p 97
###begin p 98
###xml 141 144 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12A</xref>
###xml 315 318 314 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12A</xref>
###xml 440 441 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
In mouse wild-type keratinocytes treatment with 100 muM BzATP induced acute increase in cytosolic calcium, which lasted at least 6 min (Fig. 12A). In cells bathed in low calcium BzATP induced only spiked increase in cytosolic calcium, while the prolonged sustained increase in cytosolic calcium was abolished (Fig. 12A). The spiked, short-term increase in cytosolic calcium most likely represents calcium release from intracellular stores [8]. The lack of prolonged increase in cytosolic calcium in cells bathed in extracellular medium low in calcium indicates that the BzATP-induced prolonged increase in cytosolic calcium involves calcium influx.
###end p 98
###begin p 99
###xml 115 117 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 117 118 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 151 154 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 166 169 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 0 246 0 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of BzATP in mouse wild-type normal keratinocytes on increases in cytosolic calcium (above baseline, &#916;Ca<sup>2+</sup><sub>i</sub>), in medium containing 1.2 mM Ca<sup>2+ </sup>or 1.2 mM Ca<sup>2+ </sup>plus 1.2 mM EGTA (A, C); and on the influx of ethidium bromide (Eth-Br, B, C)</bold>
###xml 250 252 246 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 252 253 248 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o</sub>
###xml 281 283 277 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 287 289 283 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 329 331 324 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 430 432 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 432 434 423 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 592 594 583 585 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
Effects of BzATP in mouse wild-type normal keratinocytes on increases in cytosolic calcium (above baseline, DeltaCa2+i), in medium containing 1.2 mM Ca2+ or 1.2 mM Ca2+ plus 1.2 mM EGTA (A, C); and on the influx of ethidium bromide (Eth-Br, B, C). Ca2+o: extracellular calcium. In A and B BzATP was added (arrows) at 100 muM. In C cells were treated with one of the indicated concentrations of BzATP for 8 hours. Levels of DeltaCa2+i (empty circles) were determined 2 min after adding BzATP; changes in Eth-Br fluorescence (filled circles) were determined 5 min after adding BzATP. Values in C are means (+/- SD). Experiments were repeated 3 times. AU - arbitrary units.
###end p 99
###begin p 100
###xml 154 157 154 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12B</xref>
###xml 230 236 230 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12A, B</xref>
###xml 296 299 296 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12C</xref>
###xml 447 450 446 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11A</xref>
###xml 452 455 451 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12C</xref>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
Experiments using mouse wild-type keratinocytes also revealed that treatment with BzATP induced an acute increase in the influx of ethidium bromide (Fig. 12B) with a time-course similar to the increase in cytosolic calcium (Figs. 12A, B). Both effects had similar dose-dependence for BzATP (Fig. 12C), and they resembled the dose-dependence of apoptosis on BzATP with threshold effects at 50-100 nM and pre-maximal responses at 100-250 muM (Figs. 11A, 12C).
###end p 100
###begin title 101
###xml 111 113 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
BzATP-induced increases in cytosolic calcium and influx of ethidium bromide depend on the expression of the P2X7 receptor
###end title 101
###begin p 102
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 172 175 172 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F13">13A</xref>
###xml 234 237 234 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F13">13B</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F13">13</xref>
Similar to the effects of BzATP on apoptosis, pre-treatment with the P2X7-receptor anti-sense oligonucleotide blocked the BzATP-induced increase in cytosolic calcium (Fig. 13A) and the BzATP-induced increase in ethidium bromide (Fig. 13B). Pre-treatment with the random-control oligonucleotides had no effect on the responses to BzATP (Fig. 13).
###end p 102
###begin p 103
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 99 101 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 101 102 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 0 156 0 152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of anti-sense P2X<sub>7 </sub>oligonucleotides on BzATP-induced increase in cytosolic calcium (&#916;Ca<sup>2+</sup><sub>i</sub>, A) and on the influx of ethidium bromide (Eth-Br, B)</bold>
###xml 248 250 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 294 296 289 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 452 454 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 454 456 444 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 457 458 447 448 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 488 489 478 479 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 167 172 <span type="species:ncbi:10090">mouse</span>
Effects of anti-sense P2X7 oligonucleotides on BzATP-induced increase in cytosolic calcium (DeltaCa2+i, A) and on the influx of ethidium bromide (Eth-Br, B). Cultured mouse wild-type normal keratinocytes were pre-treated with 100 muM anti-sense P2X7 oligonucleotides (ASO) or random-control P2X7 oligonucleotides (RCO) for 14 hours followed by 8 hours treatment with 100 muM BzATP. Control - cells treated with the vehicle of the ASO. Levels of DeltaCa2+i (A) and of Eth-Br fluorescence (B) were determined as in Fig. 12. The experiments were repeated twice with similar trends.
###end p 103
###begin title 104
The BzATP-augmented apoptosis depends on extracellular calcium
###end title 104
###begin p 105
###xml 165 168 165 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F14">14A</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
In mouse wild-type keratinocytes lowering extracellular calcium attenuated baseline apoptosis and blocked the BzATP-induced apoptosis in a dose-related manner (Fig. 14A).
###end p 105
###begin p 106
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o</sub>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. Dependence of the BzATP-induced apoptosis on extracellular calcium (Ca<sup>2+</sup><sub>o</sub>)</bold>
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 199 201 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o </sub>
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 254 256 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o </sub>
###xml 284 286 284 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 286 288 286 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o </sub>
###xml 440 441 439 440 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 601 603 598 600 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 607 609 604 606 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 829 830 824 825 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 859 861 854 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 861 863 856 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o </sub>
###xml 874 875 869 870 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
###xml 503 508 <span type="species:ncbi:10090">mouse</span>
A. Dependence of the BzATP-induced apoptosis on extracellular calcium (Ca2+o). Cultured mouse wild-type normal keratinocytes were shifted for 10 minutes to medium containing one of the indicated Ca2+o concentrations. Control (physiological) level of Ca2+o was 1.2 mM, and levels of Ca2+o were modulated by adding EGTA. Cells were treated with 100 muM BzATP (or the vehicle, Control), and changes in apoptosis were determined after 8 hours. B. Modulation of BzATP-induced apoptosis (100 muM, 8 hours) in mouse wild-type normal keratinocytes by caspase inhibitors (each added at 50 muM for 8 hours). In A and B changes in apoptosis were determined in terms of solubilized DNA. Values are means (+/- SD) of 3 experiments. Levels of apoptosis were normalized to an arbitrary value of 2 in non-treated cells. AU - arbitrary units. In A, * - p < 0.01 compared to Ca2+o 1.2 mM. In B, * - p < 0.01 compared to control.
###end p 106
###begin title 107
The BzATP-augmented apoptosis involves caspase-9 and caspase-3
###end title 107
###begin p 108
###xml 192 195 192 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F14">14B</xref>
###xml 389 392 389 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F14">14B</xref>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Treatment of mouse wild-type keratinocytes with the caspase-9 inhibitor LEHD-FMK blocked BzATP-induced apoptosis while the caspase-8 inhibitor IETD-FMK did not have a significant effect (Fig. 14B). The positive controls were DEVD-FMK (specific inhibitor of the terminal caspase-3) and zVAD-FMK (non-specific pan-caspase inhibitor) which similarly blocked the BzATP-induced apoptosis (Fig. 14B).
###end p 108
###begin title 109
Treatment with BzATP did not induce cell proliferation
###end title 109
###begin p 110
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 351 353 351 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F15">15</xref>
###xml 261 266 <span type="species:ncbi:10090">mouse</span>
To determine if the development of the large cancerous lesions in some animals in the DMBA/TPA+BzATP group was the result of a pro-mitogenic effect of BzATP, rates of DNA synthesis (in terms of [3H]thymidine incorporation) in response to BzATP were measured in mouse wild-type normal keratinocytes. Pre-treatments with the P2X7-receptor anti-sense P2X7 oligonucleotides or the random-control oligonucleotides, and treatments with BzATP had no significant effect on [3H]thymidine incorporation (Fig. 15).
###end p 110
###begin p 111
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 199 200 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 298 0 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of pre-treatment with anti-sense P2X<sub>7 </sub>oligonucleotides (ASO) or random-control P2X<sub>7 </sub>oligonucleotides (RCO) (both at 100 &#956;M for 14 hours), and of treatments with BzATP (100 &#956;M, 8 hours) on [<sup>3</sup>H]thymidine incorporation in mouse wild-type normal keratinocytes (values are means &#177; SD, n = 4)</bold>
###xml 229 234 <span type="species:ncbi:10090">mouse</span>
Effects of pre-treatment with anti-sense P2X7 oligonucleotides (ASO) or random-control P2X7 oligonucleotides (RCO) (both at 100 muM for 14 hours), and of treatments with BzATP (100 muM, 8 hours) on [3H]thymidine incorporation in mouse wild-type normal keratinocytes (values are means +/- SD, n = 4).
###end p 111
###begin title 112
Discussion
###end title 112
###begin p 113
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 556 558 556 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 790 791 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 867 869 867 869 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
The main finding of the study was that pharmacological activation of P2X7-mediated apoptosis, by local skin application of the P2X7-receptor agonist BzATP, inhibited DMBA/TPA-induced formation of skin papillomas and squamous spindle-cell carcinomas. Since the main cellular effect of BzATP was augmentation of apoptosis, this discovery provides the first direct support for the hypothesis that apoptosis is an important mechanism in vivo which controls the development and progression of neoplasia. The present findings also support the hypothesis that P2X7 is an important physiological pro-apoptotic system in epithelia, particularly those derived from the ectoderm (skin and breast), the uro-genital sinus (bladder), and the distal paramesonephric duct (uterine cervix and endometrium) [9,38,41], and Li, Qi, Zhou, Fu, Abdul-Karim, MacLennan, and Gorodeski GI: P2X7 receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric-duct origin (submitted, 2009).
###end p 113
###begin p 114
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
Co-treatment with BzATP delayed formation of DMBA/TPA-induced papillomas, and resulted in fewer and smaller papillomas. Some papillomas regressed and involuted spontaneously, as was previously described [35], and the effect was unrelated to the treatment with BzATP. However, the majority (about two thirds) either progressed into squamous spindle-cell carcinomas or persisted as non-cancerous lesions. The latter trends depended on whether animals were co-treated with BzATP; thus, in mice co-treated with BzATP the proportion of animals with cancers at week 14 was lower than in the DMBA/TPA+BzATP group (50% versus 80%) and remained relatively stable, while in the DMBA/TPA group the proportion of animals with cancers increased steadily, reaching 100% at week 24. These data suggest that local treatment with BzATP inhibits formation of DMBA/TPA-induced skin papilloma, and it can also inhibit papilloma transformation into cancers.
###end p 114
###begin p 115
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 257 259 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 593 595 593 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 975 980 975 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B, C</xref>
BzATP had little effect on the number of cancerous lesions per animal at weeks 14-28, and on the proportion of animals with cancerous lesions > 10 mm3 at weeks 14-22. In contrast, after week 23 the proportion of living animals with cancerous lesions > 10 mm3 increased in the DMBA/TPA group while it had decreased in the DMBA/TPA+BzATP group. These data suggest that local treatment with BzATP exerts an inhibitory effect on the development on skin neoplasia. Interestingly, at weeks 15-24, among animals with cancerous lesions, the proportion of living animals with lesions larger than 200 mm3 tended to be higher in the DMBA/TPA+BzATP group than in the DMBA/TPA group. This effect cannot be explained by augmented proliferation since BzATP did not stimulate DNA synthesis in cultured normal keratinocytes. Instead, the effect could be explained by comparing the survival curves (Fig. 6B) and the proportions of animals with smaller and larger size cancerous lesions (Figs. 5B, C). Thus, cancer-related deaths in the DMBA/TPA group were associated more often with smaller lesions while cancer-related deaths in the DMBA/TPA+BzATP group were associated with relatively larger lesions. This suggests that treatment with BzATP also prolonged the life of animals with developed cancers.
###end p 115
###begin p 116
###xml 167 168 167 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 325 327 325 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 363 364 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 451 453 451 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 489 491 489 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 632 633 632 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
The data showed that the main targets of BzATP in the normal skin are proliferating keratinocytes of the epidermal basal/parabasal layers and hair shafts. In these P2X7-receptor - expressing cells BzATP augmented apoptosis without evoking inflammatory changes that potentially could have been induced by activation of the P2X7 receptor [11,12]. Experiments in P2X7-deficient normal keratinocytes and in normal keratinocytes treated with anti-sense P2X7 oligonucleotides showed that the P2X7 receptor is a necessary mediator of the pro-apoptotic effect of BzATP, suggesting that the effect of BzATP is mediated by augmentation of P2X7-mediated apoptosis.
###end p 116
###begin p 117
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
Similar to the normal skin, the main targets of BzATP in papilloma tissues were P2X7-receptor expressing proliferating keratinocytes at the base of developing papillomas. The importance of this finding relates to the fact that in the mouse DMBA/TPA model, papillomas at risk for developing into cancer are characterized by rapidly proliferating keratinocytes in the basal and parabasal layers of the papilloma [35]. Since treatment with BzATP decreased the incidence of DMBA/TPA-induced papillomas and their transformation into cancer, it is likely that the cellular mechanism of BzATP action involved augmented apoptosis of proliferating papilloma keratinocytes bearing the potential of malignant transformation.
###end p 117
###begin p 118
###xml 249 253 <span type="species:ncbi:10090">mice</span>
One of the differences between BzATP effects in the normal skin and in papilloma tissues was the lack of macroscopic effects in the former, while inhibiting the development and growth of papillomas. Thus, treatment with BzATP for 16 weeks in normal mice augmented apoptosis of proliferating keratinocytes but it did not produce thinning or ulceration of the skin, as would be expected of a potent pro-apoptotic drug. Similarly, there were no significant differences in the morphological and histological characteristics of the unaffected normal skin between animals in the DMBA/TPA+BzATP group (BzATP treatment for 30 weeks) and the DMBA/TPA group. However, in the DMBA/TPA+BzATP group the enhanced apoptosis was associated with inhibition of papilloma development. The disparity between BzATP effects in normal and papilloma tissues could be related to differences in the growth rate of the respective keratinocytes. Normal skin cells are slow growing and their overall growth rate is apparently not affected by BzATP; in contrast, in the fast growing papilloma keratinocytes BzATP-induced apoptosis slows and inhibits growth.
###end p 118
###begin p 119
###xml 19 23 <span type="species:ncbi:10090">mice</span>
The data in normal mice also showed that local treatment with BzATP had no adverse systemic effects, suggesting a relatively safe profile for the drug when applied locally on the skin. These data indicate that BzATP is absorbed from the skin into the basal/parabasal epidermal regions and hair shafts. The data also suggest that the predominant effect of BzATP is induction of apoptosis at the site of application, targeting rapidly growing proliferating keratinocytes.
###end p 119
###begin p 120
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 407 409 407 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 680 682 680 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 712 713 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
In contrast to papillomas, the expression level of P2X7 receptors in DMBA/TPA-induced cancer cells was low, as was evident by three assays: in-situ immunoreactivity, Western blots, and qPCR. These findings are similar to those reported in non-melanoma skin cancer cells [30] and in uterine, bladder and breast epithelial cancers [9,38,41], and Li, Qi, Zhou, Fu, Abdul-Karim, MacLennan, and Gorodeski GI: P2X7 receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric-duct origin (submitted, 2009). The findings suggest that the rapid proliferation of cancer cells could be in part due to the low expression of the P2X7 receptor and to attenuated P2X7-mediated apoptosis. Treatment with BzATP augmented apoptosis even in cancer cells expressing low levels of the receptor, but the effect was smaller than in normal or papilloma cells. The significance of this effect is at present unclear although it could have modified the biological behavior of the cancers and have contributed to the prolongation of life in the affected animals, as was discussed above.
###end p 120
###begin p 121
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 343 344 343 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 425 427 425 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 804 806 804 806 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 1517 1518 1517 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1519 1520 1519 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1583 1584 1583 1584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1755 1757 1755 1757 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 1864 1867 1864 1867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1878 1880 1878 1880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 1685 1690 <span type="species:ncbi:10090">mouse</span>
Until recently little was known about the mechanisms of P2X7-receptor - apoptosis in the skin, and one of the objectives of the present study was to begin to understand the signaling pathways and molecular mechanisms that are involved in BzATP action in keratinocytes. The data suggest that, similar to uterine epithelial cells [8,18], the P2X7-receptor - apoptosis in keratinocytes depends on enhanced calcium influx via P2X7 pores, and is mediated by the caspase-9 - mitochondrial pathway. The following experimental findings in the present study support this hypothesis: (a) Treatment with BzATP induced formation of pores and enhanced calcium influx; (b) the BzATP-induced apoptosis, pore formation and the augmented and prolonged calcium influx were critically dependent on the expression of the P2X7 receptor; (c) the BzATP-induced apoptosis, pore formation and the augmented calcium influx had similar dose-dependence on BzATP; (d) the BzATP-induced pore formation and the augmented calcium influx began shortly (30-60 seconds) after adding BzATP. In contrast, the BzATP-induced apoptosis required hours of treatment with BzATP, commensurate with a gene-mediated effect; (e) the BzATP-induced apoptosis depended on the presence of extracellular calcium at a physiological concentration of 1.2 mM, and on calcium influx; (f) the BzATP-induced apoptosis could be blocked by co-treatment with inhibitors of caspase-9 and caspase-3, but not of caspase-8. Since caspase-3 is a terminal step in the caspase cascade [5,6], a possible interpretation of the present results is that P2X7-receptor - apoptosis is mediated by the caspase-9 (mitochondrial) pathway. Collectively the data in mouse keratinocytes suggest that BzATP-dependent activation of the P2X7 receptor involves formation of pores in the plasma membrane, and that facilitated uncontrolled influx of Ca2+ via the P2X7 pores stimulates apoptosis by the mitochondrial - caspase-9 pathway.
###end p 121
###begin p 122
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 105 107 105 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 189 191 189 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 267 269 267 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 356 358 356 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 689 691 689 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
P2X7 pores are believed to be formed of channels composed of pannexins [42,43] and ectodomains of the P2X7 molecule [23,42]. However, the ability of agonists to induce apoptosis via the P2X7 pore mechanism is determined primarily by the cellular expression of the P2X7 receptor [13,23]. The present study showed that papilloma keratinocytes express the P2X7 receptor; therefore, the high expression levels of the receptor in papilloma cells and the significant apoptotic effects in response to BzATP could explain the inhibitory effect of BzATP on papilloma development. In contrast, the lesser effect of BzATP in skin cancer cells could be explained by the low expression level of the P2X7 receptor in the cancer cells.
###end p 122
###begin p 123
###xml 101 102 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 338 340 338 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 538 540 538 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 911 913 911 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 961 962 961 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1096 1098 1096 1098 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 1191 1192 1191 1192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1366 1368 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
At present little is known whether the neoplastic transformation induces lesser expression of the P2X7-receptor, or whether the neoplastic transformation is triggered preferentially in cells expressing low levels of the receptor. The former possibility is supported by data in endometrial and bladder cells where low expression of the P2X7 receptor was found already in pre-cancerous and early cancerous cells but not in hyperplastic benign cells [38]. Accordingly, the carcinogenic process could have induced lesser expression of the P2X7 already at early stages of cancer development. On the other hand the possibility that the neoplastic transformation is triggered preferentially in cells expressing low levels of the receptor is supported by data as well, and it could be more fundamental to the understanding of epithelial-cell carcinogenesis. Thus, in uterine cervical epithelia low expression of the P2X7 receptor was found already in dysplastic cells [9]. Since only a small fraction of cervical dysplasia cases progresses to cancer [44-46], it is possible that low expression of the P2X7 receptor in the cervix precedes the neoplastic transformation. Accordingly, abrogation of P2X7-mediated apoptosis could be responsible for the preservation of genetically aberrant cells that are susceptible to carcinogenic stimuli, favoring neoplastic transformation [47].
###end p 123
###begin p 124
###xml 176 178 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
The present data showed only partial inhibition (by about 50%) of papilloma and cancer formation in BzATP-treated mice. The experiments used the relatively low dose of 1 mug/cm2 BzATP, based on the 100 muM concentration used in experiments with cultured cells. The study was not designed to test higher doses and different frequencies of drug administration, and it is possible that higher doses and/or more frequent applications could produce greater inhibition papillomas and cancers. Additional studies are needed to test this possibility.
###end p 124
###begin p 125
###xml 137 139 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 573 574 573 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 525 530 <span type="species:ncbi:10090">mouse</span>
###xml 952 958 <span type="species:ncbi:9606">humans</span>
In addition to improving our understanding of the biogenesis of skin cancers and possibly other types of epithelial cancers where the P2X7 controls cell growth, the present results provide a basis for continued research of novel chemotherapeutic growth-preventive modalities through regulation of apoptosis. The rationale is that epithelial cancers usually develop from premalignant lesions, e.g. papilloma, and the cancer risk of premalignant epithelial lesions may vary from 0.1% to 20% [48-50]. The present results in the mouse model showed that local treatment with P2X7-receptor agonists could inhibit the development of papillomas and inhibit the transformation of papillomas into cancers. BzATP appears to be a candidate chemotherapeutic growth-preventive drug for skin papillomas, with an apparent low risk profile of adverse events when administered locally on the skin. However, more studies are needed to test whether BzATP could be used in humans.
###end p 125
###begin title 126
Conclusion
###end title 126
###begin p 127
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 129 134 <span type="species:ncbi:10090">mouse</span>
* P2X7-dependent apoptosis is an important mechanism that controls the development and progression of epidermal neoplasia in the mouse.
###end p 127
###begin p 128
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 81 83 81 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
* P2X7-dependent apoptosis in keratinocytes is mediated by calcium influx via P2X7 pores, and involves the caspase-9 (mitochondrial) pathway.
###end p 128
###begin p 129
###xml 128 130 128 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
* The diminished pro-apoptotic effect of BzATP in mouse cancer keratinocytes is possibly the result of low expression of the P2X7 receptor.
###end p 129
###begin p 130
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
* Activation of P2X7-dependent apoptosis, e.g. with BzATP could be a novel chemotherapeutic growth-preventive modality for papillomas and epithelial cancers in vivo.
###end p 130
###begin title 131
Competing interests
###end title 131
###begin p 132
CytoCore Inc. funded a small part of the study but it has no financial interest in the study. Dr. Gorodeski was paid consultant to CytoCore Inc. and he holds restricted stocks of CytoCore. The ties between Dr. Gorodeski and CytoCore were severed in March 2008 and Dr. Gorodeski has no financial interest in the study. None of the other authors had any ties with CytoCore. Neither Dr. Gorodeski, nor any of the other authors have other financial or non-financial competing interests. University Hospital CASE Medical Center and Case Western Reserve University have a financial interest in the study
###end p 132
###begin title 133
Authors' contributions
###end title 133
###begin p 134
WF carried out the animals' experiments. TM supervised the animals' experiments. XQ carried out the immunostaining assays. LL assisted with the animals' experiments. LZ and XL carried out the cell culture assays. BCW participated in its design of the animals experiments. HG participated in its design of the study and carried out the data analysis. FWAK evaluated the pathology results. GIG conceived the study; participated in its design and coordination; and drafted the manuscript. All authors read and approved the final manuscript.
###end p 134
###begin title 135
Pre-publication history
###end title 135
###begin p 136
The pre-publication history for this paper can be accessed here:
###end p 136
###begin p 137

###end p 137
###begin title 138
Acknowledgements
###end title 138
###begin p 139
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 427 428 427 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
The study was supported in part by NIH grant AG15955 and by an unrestricted grant by CytoCore Inc. to GIG. Dr. Eiran Z. Gorodeski (Department of Cardiovascular Medicine, Cleveland Clinic) is acknowledged for assistance in data analysis. Dr. Kevin Cooper (Chairman of Dermatology, Case Western Reserve University) is acknowledged for providing useful advice. P2X7-/-Pfizer mice were obtained from Pfizer Inc. (New York, NY). P2X7-/-GSK mice were obtained from GlaxoSmithKline (Brentford, Middlesex, United Kingdom).
###end p 139
###begin article-title 140
Cancer stem cells: implications for the progression and treatment of metastatic disease
###end article-title 140
###begin article-title 141
Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment
###end article-title 141
###begin article-title 142
Cell death: the significance of apoptosis
###end article-title 142
###begin article-title 143
Mechanisms and functions of cell death
###end article-title 143
###begin article-title 144
Mechanisms of cell death
###end article-title 144
###begin article-title 145
Apoptosis, necrosis and cellular senescence: chaperone occupancy as a potential switch
###end article-title 145
###begin article-title 146
Apoptosis: identification of dying cells
###end article-title 146
###begin article-title 147
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 36 41 <span type="species:ncbi:9606">human</span>
P2X7-receptor mediated apoptosis of human cervical epithelial cells
###end article-title 147
###begin article-title 148
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
The P2X7 Receptor: A novel biomarker of uterine epithelial cancers
###end article-title 148
###begin article-title 149
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
EGF facilitates epinephrine inhibition of P2X7-receptor mediated pore formation and apoptosis: a novel signaling network
###end article-title 149
###begin article-title 150
Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides
###end article-title 150
###begin article-title 151
Receptors for purines and pyrimidines
###end article-title 151
###begin article-title 152
Molecular physiology of P2X receptors
###end article-title 152
###begin article-title 153
ATP released by LPS increases nitric oxide production in raw 264.7 macrophage cell line via P2Z/P2X7 receptors
###end article-title 153
###begin article-title 154
###xml 77 82 <span type="species:ncbi:9606">human</span>
Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes
###end article-title 154
###begin article-title 155
Effect of ATP on intracellular pH in pancreatic ducts involves P2X7 receptors
###end article-title 155
###begin article-title 156
Hypertonic stress increases T-cell Interleukin-2 expression through a mechanism that involves ATP release, P2 Receptor, and p38 MAPK activation
###end article-title 156
###begin article-title 157
###xml 59 64 <span type="species:ncbi:9606">human</span>
Anti-apoptotic effects of estrogen in normal and in cancer human cervical epithelial cells
###end article-title 157
###begin article-title 158
###xml 89 94 <span type="species:ncbi:9606">human</span>
Extracellular ATP triggers IL-1beta release by activating the purinergic P2Z receptor of human macrophages
###end article-title 158
###begin article-title 159
The role of the purinergic P2X7 receptor in inflammation
###end article-title 159
###begin article-title 160
Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor
###end article-title 160
###begin article-title 161
Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65
###end article-title 161
###begin article-title 162
###xml 15 17 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 38 41 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7-j</sub>
###xml 122 124 122 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization
###end article-title 162
###begin article-title 163
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human epidermal and monocyte-derived langerhans cells express functional P2X receptors
###end article-title 163
###begin article-title 164
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse dendritic cells express the P2X7 purinergic receptor: Characterization and possible participation in antigen presentation
###end article-title 164
###begin article-title 165
###xml 70 75 <span type="species:ncbi:9606">human</span>
Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes
###end article-title 165
###begin article-title 166
###xml 115 120 <span type="species:ncbi:9606">human</span>
Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes
###end article-title 166
###begin article-title 167
###xml 104 109 <span type="species:ncbi:9606">human</span>
Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes
###end article-title 167
###begin article-title 168
Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers
###end article-title 168
###begin article-title 169
Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells
###end article-title 169
###begin article-title 170
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human melanomas express functional P2X7 receptors
###end article-title 170
###begin article-title 171
###xml 118 123 <span type="species:ncbi:9606">human</span>
Purinergic receptors are part of a signaling system for keratinocyte proliferation, differentiation, and apoptosis in human fetal epidermis
###end article-title 171
###begin article-title 172
###xml 100 105 <span type="species:ncbi:10090">mouse</span>
Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin
###end article-title 172
###begin article-title 173
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse care and husbandry
###end article-title 173
###begin article-title 174
###xml 92 97 <span type="species:ncbi:9606">human</span>
The high-risk benign tumor: evidence from the two-stage skin cancer model and relevance for human cancer
###end article-title 174
###begin article-title 175
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Altered cytokine production in mice lacking P2X(7) receptors
###end article-title 175
###begin article-title 176
Purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X7-independent mechanism
###end article-title 176
###begin article-title 177
###xml 27 29 27 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells
###end article-title 177
###begin article-title 178
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Cloning and functional characterisation of the mouse P2X7 receptor
###end article-title 178
###begin article-title 179
Changes in Tight Junctional Resistance of the Cervical Epithelium are Associated with Modulation of Content and Phosphorylation of Occludin 65 KDa and 50 KDa forms
###end article-title 179
###begin article-title 180
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
Micro-RNAs miR-186 and miR-150 downregulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3'-untranslated region of the gene that decrease steady-state levels of the transcript
###end article-title 180
###begin article-title 181
Pannexin1 is part of the pore forming unit of the P2X7R death complex
###end article-title 181
###begin article-title 182
P2X7 receptor-Pannexin1 complex: Pharmacology and signaling
###end article-title 182
###begin article-title 183
###xml 0 20 <span type="species:ncbi:10566">Human papillomavirus</span>
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
###end article-title 183
###begin article-title 184
###xml 39 44 <span type="species:ncbi:9606">women</span>
Long-term outcome and relative risk in women with atypical squamous cells of undetermined significance
###end article-title 184
###begin article-title 185
Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix
###end article-title 185
###begin article-title 186
Prognostic value of apoptotic index in cutaneous basal cell carcinomas of head and neck
###end article-title 186
###begin article-title 187
Prognosis of oral pre-malignant lesions: Significance of clinical, histopathological, and molecular biological characteristics
###end article-title 187
###begin article-title 188
###xml 35 38 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">st </sup>
The actinic (solar) keratosis: A 21st century perspective
###end article-title 188
###begin article-title 189
Management of cervical premalignant lesions
###end article-title 189

